Company’s 36-month beta value is -0.48.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MLEC is 10.45M, and currently, short sellers hold a 0.98% ratio of that floaft. The average trading volume of MLEC on April 21, 2025 was 17.60K shares.
MLEC) stock’s latest price update
The stock price of Moolec Science SA (NASDAQ: MLEC) has dropped by -3.87 compared to previous close of 0.68. Despite this, the company has seen a fall of -3.00% in its stock price over the last five trading days. accessnewswire.com reported 2025-04-21 that LUXEMBOURG, LU / ACCESS Newswire / April 21, 2025 / Moolec Science SA (NASDAQ:MLEC) (“The Company” or “Moolec”), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the “BCA”) with Bioceres Group Limited (“Bioceres Group”) and other related entities in an all-stock transaction (the “Business Combination”). Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC (“Nutrecon”), and Gentle Technologies Corp (“Gentle Tech”, and together with Bioceres Group and Nutrecon, the “Contributed Entities”), resulting in an enlarged corporate structure with Moolec as the parent company.
MLEC’s Market Performance
Moolec Science SA (MLEC) has experienced a -3.00% fall in stock performance for the past week, with a -9.72% drop in the past month, and a -22.53% drop in the past quarter. The volatility ratio for the week is 11.25%, and the volatility levels for the past 30 days are at 10.46% for MLEC. The simple moving average for the past 20 days is 1.03% for MLEC’s stock, with a -22.12% simple moving average for the past 200 days.
Analysts’ Opinion of MLEC
Many brokerage firms have already submitted their reports for MLEC stocks, with ROTH MKM repeating the rating for MLEC by listing it as a “Buy.” The predicted price for MLEC in the upcoming period, according to ROTH MKM is $5 based on the research report published on September 27, 2023 of the previous year 2023.
MLEC Trading at -7.01% from the 50-Day Moving Average
After a stumble in the market that brought MLEC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.00% of loss for the given period.
Volatility was left at 10.46%, however, over the last 30 days, the volatility rate increased by 11.25%, as shares sank -9.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.56% lower at present.
During the last 5 trading sessions, MLEC fell by -4.48%, which changed the moving average for the period of 200-days by -40.46% in comparison to the 20-day moving average, which settled at $0.6429. In addition, Moolec Science SA saw -18.75% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MLEC
Current profitability levels for the company are sitting at:
- -1.17 for the present operating margin
- -0.08 for the gross margin
The net margin for Moolec Science SA stands at -1.06. The total capital return value is set at -0.37. Equity return is now at value -174.68, with -31.42 for asset returns.
Based on Moolec Science SA (MLEC), the company’s capital structure generated 0.89 points at debt to capital in total, while cash flow to debt ratio is standing at -0.26. The debt to equity ratio resting at 7.9. The interest coverage ratio of the stock is -4.19.
Currently, EBITDA for the company is -6.16 million with net debt to EBITDA at -3.84. When we switch over and look at the enterprise to sales, we see a ratio of 5.9. The receivables turnover for the company is 2.86for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.48.
Conclusion
In a nutshell, Moolec Science SA (MLEC) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
